The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: February 2012

Friday Science Review: February 24, 2012

In my first contribution to the Cross-Border Biotech Blog’s Friday Science Review we have a promising advance in the treatment of Huntington’s disease by an international collaboration led by researchers from the Department of Pharmacology at the University of Alberta and another look at the surprisingly small number of critical genes in organisms by the [...]

Some Partnering Basics: Part 16 of Valuation and Other Biotech Mysteries

[Ed. This is the sixteenth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] If partnering is basically the process of selling an asset, the first step is to let people know [...]

Monday Biotech Deal Review: February 13, 2012

Welcome to your Monday Biotech Deal Review for February 13, 2012.  There was some interesting biotech activity over the previous two weeks, including the closing by Oncolytics of its $18.5M equity financing and the withdrawal by Valeant of its offer to acquire ISTA Pharmaceuticals and its acquisition of a Brazilian food and sport supplement company.  [...]

Friday Science Review: February 10, 2012

Automated Regulation of Inhibitory Feedback Signalling Leads to Rapid and Robust Expansion of Cord Blood-Derived Hematopoietic Stem Cells University of Toronto ♦ Genomics Institute of the Novartis Research Foundation ♦ Heart and Stroke/Richard Lewar Centre of Excellence ♦ McEwen Centre for Regenerative Medicine Published in Cell Stem Cell, February 3, 2012 The greatest current justification for the storage [...]

Friday Science Review: February 3, 2012

Pathogenesis of Paediatric Glioblastoma Multiforme McGill University ♦ Genome Quebec Innovation Centre Published in Nature, January 29, 2012 Researchers have not only discovered the first recurring mutation in a human histone but have uncovered a key pathway involved in the formation of paediatric glioblastoma multiforme (GBM). This highly aggressive form of cancer is almost always lethal. [...]

Partner, Sell, or Go it alone: Part 15 of Valuation and Other Biotech Mysteries

[Ed. This is the fifteenth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] This is a discussion that the management and board of a company need to start as the company [...]

Follow

Get every new post delivered to your Inbox.

Join 92 other followers